BACKGROUND AND OBJECTIVE: The co-morbidity of depressive disorder and chronic kidney failure is remarkably common. However, knowledge about the influence of haemodialysis on the serum concentration of antidepressants is sparse. In this study we examined the influence of haemodialysis on the serum concentrations of the antidepressants amitriptyline (and its active metabolite nortriptyline) and mirtazapine. METHODS: The authors retrospectively evaluated therapeutic drug monitoring (TDM)-analyses obtained in eight different regional medical dialysis centres before and after haemodialysis and compared serum concentrations of amitriptyline and mirtazapine using t-tests. RESULTS: Mean serum concentrations of the sum of amitriptyline + nortriptyline (before: 75.52 ng/mL; after: 59.35 ng/mL; p < 0.001) and mirtazapine (before: 53.45 ng/mL; after: 38.31 ng/mL; p < 0.036) decreased significantly with haemodialysis. Haemodialysis patients received rather low doses of amitriptyline (mean 36.5 mg; SD 17.6; range 10-75 mg) and mirtazapine (mean 24.7 mg; SD 9.1; range 15-45 mg). CONCLUSION: For haemodialysis patients with depression an adequate antidepressant drug dosage must be administered. TDM is necessary in order to optimize antidepressant therapy in patients with chronic kidney disease.
BACKGROUND AND OBJECTIVE: The co-morbidity of depressive disorder and chronic kidney failure is remarkably common. However, knowledge about the influence of haemodialysis on the serum concentration of antidepressants is sparse. In this study we examined the influence of haemodialysis on the serum concentrations of the antidepressants amitriptyline (and its active metabolite nortriptyline) and mirtazapine. METHODS: The authors retrospectively evaluated therapeutic drug monitoring (TDM)-analyses obtained in eight different regional medical dialysis centres before and after haemodialysis and compared serum concentrations of amitriptyline and mirtazapine using t-tests. RESULTS: Mean serum concentrations of the sum of amitriptyline + nortriptyline (before: 75.52 ng/mL; after: 59.35 ng/mL; p < 0.001) and mirtazapine (before: 53.45 ng/mL; after: 38.31 ng/mL; p < 0.036) decreased significantly with haemodialysis. Haemodialysis patients received rather low doses of amitriptyline (mean 36.5 mg; SD 17.6; range 10-75 mg) and mirtazapine (mean 24.7 mg; SD 9.1; range 15-45 mg). CONCLUSION: For haemodialysis patients with depression an adequate antidepressant drug dosage must be administered. TDM is necessary in order to optimize antidepressant therapy in patients with chronic kidney disease.
Authors: Camila Martiny; Adriana Cardoso de Oliveira e Silva; José Pedro Simões Neto; Antonio Egidio Nardi Journal: Compr Psychiatry Date: 2010-12-28 Impact factor: 3.735
Authors: Antonio Alberto Lopes; Justin M Albert; Eric W Young; Sudtida Satayathum; Ronald L Pisoni; Vittorio E Andreucci; Donna L Mapes; Nancy A Mason; Shunichi Fukuhara; Björn Wikström; Akira Saito; Friedrich K Port Journal: Kidney Int Date: 2004-11 Impact factor: 10.612
Authors: Matthew T Olson; Autumn Breaud; Robert Harlan; Nkechinyere Emezienna; Sabitha Schools; Alfred L Yergey; William Clarke Journal: Clin Chem Date: 2013-02-20 Impact factor: 8.327
Authors: Christopher Yates; Tais Galvao; Kevin M Sowinski; Karine Mardini; Tudor Botnaru; Sophie Gosselin; Robert S Hoffman; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum Journal: Semin Dial Date: 2014-04-09 Impact factor: 3.455